全文获取类型
收费全文 | 737篇 |
免费 | 55篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 18篇 |
妇产科学 | 16篇 |
基础医学 | 89篇 |
口腔科学 | 8篇 |
临床医学 | 57篇 |
内科学 | 94篇 |
皮肤病学 | 6篇 |
神经病学 | 153篇 |
特种医学 | 6篇 |
外科学 | 171篇 |
综合类 | 3篇 |
预防医学 | 67篇 |
眼科学 | 11篇 |
药学 | 33篇 |
肿瘤学 | 59篇 |
出版年
2022年 | 6篇 |
2021年 | 13篇 |
2020年 | 7篇 |
2019年 | 23篇 |
2018年 | 14篇 |
2017年 | 9篇 |
2016年 | 5篇 |
2015年 | 9篇 |
2014年 | 21篇 |
2013年 | 44篇 |
2012年 | 39篇 |
2011年 | 34篇 |
2010年 | 20篇 |
2009年 | 25篇 |
2008年 | 24篇 |
2007年 | 31篇 |
2006年 | 30篇 |
2005年 | 36篇 |
2004年 | 32篇 |
2003年 | 32篇 |
2002年 | 16篇 |
2001年 | 27篇 |
2000年 | 19篇 |
1999年 | 19篇 |
1998年 | 6篇 |
1996年 | 4篇 |
1995年 | 5篇 |
1994年 | 18篇 |
1993年 | 14篇 |
1992年 | 18篇 |
1991年 | 25篇 |
1990年 | 11篇 |
1989年 | 9篇 |
1988年 | 8篇 |
1987年 | 9篇 |
1986年 | 9篇 |
1985年 | 5篇 |
1983年 | 12篇 |
1982年 | 5篇 |
1981年 | 5篇 |
1979年 | 6篇 |
1978年 | 8篇 |
1975年 | 5篇 |
1974年 | 7篇 |
1973年 | 5篇 |
1971年 | 6篇 |
1970年 | 7篇 |
1969年 | 8篇 |
1968年 | 5篇 |
1947年 | 3篇 |
排序方式: 共有793条查询结果,搜索用时 15 毫秒
21.
22.
23.
24.
25.
Enver Akalin Rajani Dinavahi Rex Friedlander Scott Ames Graciela de Boccardo Vinita Sehgal Bernd Schr?ppel Madhu Bhaskaran Susan Lerner Marileno Fotino Barbara Murphy Jonathan S. Bromberg 《Clinical journal of the American Society of Nephrology》2008,3(4):1160-1167
Background and objectives: The objective of this study was to investigate the effects of desensitization protocols using intravenous Ig with or without plasmapheresis in patients with donor-specific anti-HLA antibodies on prevention of antibody-mediated rejection and downregulation of donor-specific antibodies.Design, setting, participants, & measurements: Thirty-five complement-dependent cytotoxicity T cell cross-match–negative but complement-dependent cytotoxicity B cell and/or flow cytometry cross-match–positive kidney transplant recipients were treated with high-dosage intravenous Ig plus Thymoglobulin induction treatment. Donor-specific antibody strength was stratified as strong, medium, or weak by Luminex flow beads. Group 1 patients had weak/moderate and group 2 strong donor-specific antibodiesResults: Whereas no group 1 patients had acute rejection, 66% of group 2 had acute rejection (44% antibody-mediated rejection, 22% cellular rejection). The protocol was then changed to the addition of peritransplantation plasmapheresis to patients with strong donor-specific antibodies (group 3). This change resulted in a dramatic decrease in the acute rejection rate to 7%. During a median 18 mo of follow-up, patient survival was 100, 100, and 93% and graft survival was 100, 78, and 86% in groups 1, 2, and 3, respectively. During follow-up, 17 (52%) patients lost donor-specific antibodies completely, and 10 (30%) lost some of donor-specific antibodies and/or decreased the strength of existing donor-specific antibodies.Conclusions: These results indicated that in patients with strong donor-specific antibodies, the addition of plasmapheresis to high-dosage intravenous Ig decreases the incidence of acute rejection. The majority of the patients, whether they received intravenous Ig alone or with plasmapheresis, lost their donor-specific antibodies during follow-up.Donor-specific anti-HLA antibodies (DSA) in patients who are sensitized through pregnancy, previous blood transfusions, or organ transplantation is an important obstacle in kidney transplantation. Sensitized patients wait longer on the deceased-donor transplantation list, may not receive a transplant, and may have greater morbidity and mortality. Some sensitized patients may have living donor candidates, but transplantation cannot be performed because of cross-match positivity. Recent desensitization protocols using the combination of plasmapheresis (PP) or immunoadsorption to remove DSA and/or intravenous Ig (IVIG) and rituximab to downregulate antibody-mediated immune responses have made kidney transplantation feasible by abrogating complement-dependent cytotoxicity (CDC) T cell cross-match positivity. In previous studies, two protocols were examined: High-dosage IVIG (2.0 g/kg) (1–3) and PP with low-dosage IVIG (100 mg/kg after each PP session) (4–8); however, acute antibody-mediated rejection (AMR) continued to be an important barrier and was still observed in at least 30 to 40% of the recipients included in these desensitization protocols, even when rituximab was added to the protocol.Whereas CDC T cell cross-match positivity is an absolute contraindication to kidney transplantation, the clinical significance of CDC B cell or flow cytometry (FC) T and/or B cell cross-match positivity are less clear. Most studies have demonstrated that CDC T cell cross-match–negative but CDC B or FC T/B cell cross-match–positive patients with DSA are at higher risk for developing acute cellular, antibody-mediated, and chronic rejection and graft loss (9,10). The role of desensitization protocols for these patients has not been studied in a large cohort. We previously reported our initial experience using low-dosage IVIG (300 mg/kg) and Thymoglobulin induction treatment in 15 patients (11,12). Because of early AMR in three patients, the IVIG dosage was increased to a total of 2.0 mg/kg in subsequent patients. Now, we present our experience in CDC T cell–negative but CDC B cell or FC T and/or B cell cross-match–positive kidney transplant recipients with DSA, who were stratified according to mean fluorescence indices of Luminex flow beads. The results showed that patients with strong DSA were at much higher risk for developing acute AMR early after transplantation, and the addition of peritransplantation PP to high-dosage IVIG and Thymoglobulin treatment significantly decreased the incidence of AMR. The majority of the patients, whether they received IVIG alone or with PP, lost DSA during follow-up. 相似文献
26.
J Waisberg M Hamada J E Gon?alves M Messias S H Bromberg P P Jatobá A C de Godoy 《Arquivos de gastroenterologia》1990,27(2):53-61
Twenty-one patients with carcinoid tumors have been analysed. Out of 18 patients the diagnostic was made at operation and out of 3 by autopsy. The most frequent sites of the primary tumors were the appendix (38.1%), ileum (23.8%) and colon (19.9%). Asymptomatic tumors were found incidentally in 10 patients (55.5%). The symptomatic neoplasms were more common in the ileum. No one patients in this series obtained the diagnostic of carcinoid tumors before operation or autopsy. It was not observed the malignant carcinoid syndrome. Sixteen patients (88.8%) were submitted to resection and the mean survival was 10.7 years. Two patients (11.1%) were submitted to palliative operations and the mean survival was 3.5 months. The incidence of metastases in cases with carcinoid greater than 2.0 cm in diameter was 71.4%; on the other hand, the patients with carcinoids 2.0 cm in diameter or smaller than this size disclosed metastases in 7.6%. No patients with appendix carcinoid showed metastases and all patients with metastases presented ileum or colon carcinoids. In this series, the prognostic was related with the lesion's size, the localization of the tumor in the gastrointestinal tract and with the resection or not of the primary neoplasm. 相似文献
27.
Jeffrey V. Lazarus Daniel J. Bromberg Julia del Amo Ole Norgaard Javier García-Samaniego Aina Casellas José Luis Calleja Ana Requena-Méndez 《Enfermedades infecciosas y microbiología clínica》2019,37(4):222-230
Introduction
Spain, which has one of the largest migrant populations in Europe, has committed to eliminating the hepatitis C virus (HCV). The aim of this study was to estimate the prevalence of HCV among migrant groups in Spain, a country of 46 million people, with an estimated HCV-antibody prevalence of 1.7%.Methods
Studies on HCV and migration in Spain were identified by systematically searching three databases from the first records to 30 November 2017, and consulting experts at the Ministry of Health and in the 17 Spanish autonomous communities. A meta-analysis was conducted to determine pooled HCV prevalence for the general migrant population. Prevalences were also calculated for high-risk migrant populations and populations who had undergone hospital screening, stratified by region of origin.Results
Out of 243 studies identified, 26 met the eligibility criteria. The meta-analysis of the general migrant population found HCV antibody prevalence to be 1.6%. Migrants originating from European countries, including those at high or moderate risk for HCV, had the highest pooled prevalence (7.1%). In the general migrant population, prevalence was highest among sub-Saharan African migrants (3.1%) and lowest among Latin American migrants (0.2%).Conclusion
Based on the limited available data, the prevalence among the general migrant population was found to be the same as the general Spanish population. Further research is needed to more accurately determine HCV prevalence for the overall migrant population and specific migrant subpopulations with a higher risk in the country as a whole and in each of Spain's 17 autonomous communities. 相似文献28.
Efficacy and safety of a T‐type calcium channel blocker in patients with neuropathic pain: A proof‐of‐concept,randomized, double‐blind and controlled trial
下载免费PDF全文
![点击此处可从《European Journal of Pain》网站下载免费的PDF全文](/ch/ext_images/free.gif)
N. Kerckhove B. Pereira S. Soriot‐Thomas H. Alchaar R. Deleens V.S. Hieng E. Serra M. Lanteri‐Minet P. Arcagni P. Picard D. Lefebvre‐Kuntz C. Maindet G. Mick L. Balp C. Lucas C. Creach M. Letellier V. Martinez M. Navez D. Delbrouck E. Kuhn E. Piquet E. Bozzolo C. Brosse B. Lietar F. Marcaillou A. Hamdani N. Leroux‐Bromberg Y. Perier P. Vergne‐Salle C. Gov N. Delage D. Gillet S. Romettino D. Richard C. Mallet L. Bernard C. Lambert C. Dubray C. Duale A. Eschalier 《European Journal of Pain》2018,22(7):1321-1330
29.
30.